SynthesisBritish journal of anaesthesia2025
Effect of intraoperative dexmedetomidine on prognosis in patients with cancer undergoing surgical procedures: a systematic review and meta-analysis.
Synthesis in British journal of anaesthesia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mechanism, Dose, and Administration of Dexmedetomidine in Managing Visceral Pain Associated With Surgery: A Narrative Review.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Effect of intraoperative dexmedetomidine on prognosis in patients with cancer undergoing surgical procedures. Responses to recent commentary.British journal of anaesthesia · 2025Article
- Anti-tumour effects of perioperative ketamine in lung cancer: a non-randomised, exploratory biomarker study.British journal of anaesthesia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer places a significant burden on patients and healthcare systems. Dexmedetomidine, an α
methodsWe conducted a comprehensive search of PubMed, Web of Science, Embase, and the China National Knowledge Infrastructure up to April 2024. Two researchers extracted data including authors, year, country, study design, follow-up, patient characteristics, and hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival and recurrence-free survival. Quality assessment was conducted using the Cochrane tool for randomised controlled trials (RCTs) and the Newcastle-Ottawa Scale for retrospective studies.
resultsThe review identified 12 studies: six RCTs and six retrospective studies. In the RCTs, intraoperative dexmedetomidine showed no significant effect on overall survival (odds ratio [OR] 0.87, 95% CI 0.67-1.13, P=0.29) but improved recurrence-free survival (OR 0.65, 95% CI 0.47-0.91, P=0.01). Retrospective studies indicated that dexmedetomidine was associated with decreased overall survival (post-matching HR 1.52, 95% CI 1.15-2.00, P=0.003), and had no significant effect on recurrence-free survival (post-matching HR 1.29, 95% CI 0.96-1.72, P=0.09).
conclusionsMeta-analysis reveals inconsistent evidence regarding impact of intraoperative dexmedetomidine on cancer outcomes after surgery. RCTs suggest improved recurrence-free survival, whereas retrospective studies suggest potential reductions in overall survival. The limited and contradictory data highlight the necessity for more high-quality RCTs to clarify the effects of dexmedetomidine on survival and prognosis in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.